What is Akermin?
Headquartered at the prestigious BRDG Park within the Danforth Plant Science Center in St. Louis, Akermin operates at the intersection of biotechnology and industrial engineering. The company specializes in the development of a proprietary Biocatalyst Delivery System, a sophisticated platform designed to integrate enzymes into conventional industrial processes. By facilitating energy-efficient and sustainable carbon dioxide management, Akermin addresses the growing global demand for green manufacturing solutions. Its multi-disciplined approach allows for the seamless retrofitting of existing infrastructure, positioning the firm as a key enabler for heavy industries aiming to reduce their environmental footprint without compromising operational throughput. The company's focus on biocatalysis represents a significant departure from traditional, energy-intensive carbon capture methods, offering a more sustainable pathway for industrial decarbonization.
How much funding has Akermin raised?
Akermin has raised a total of $12.6M across 4 funding rounds:
Unspecified
$600K
Unspecified
$6.1M
Unspecified
$4.1M
Debt
$1.8M
Unspecified (2009): $600K, investors not publicly disclosed
Unspecified (2009): $6.1M, investors not publicly disclosed
Unspecified (2010): $4.1M, investors not publicly disclosed
Debt (2013): $1.8M, investors not publicly disclosed
Key Investors in Akermin
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Akermin?
With the recent influx of capital, Akermin is well-positioned to accelerate its commercialization roadmap and expand its market reach. The strategic focus will likely shift toward optimizing the scalability of its Biocatalyst Delivery System and forging partnerships with major industrial players seeking to meet stringent environmental, social, and governance (ESG) mandates. As the regulatory landscape for carbon emissions continues to tighten, Akermin's ability to provide cost-effective, enzyme-based solutions will be a primary driver of its future growth. The company is expected to leverage these funds to enhance its R&D capabilities, potentially exploring new applications for its biocatalytic platform in sectors beyond its current scope, thereby diversifying its revenue streams and strengthening its competitive moat in the rapidly evolving cleantech ecosystem.
See full Akermin company page
